Does MDwise Cover Eliquis? A Complete Insurance and Clinical Guide

What Is MDwise and How Does Its Drug Coverage Work?

MDwise is a not-for-profit Medicaid managed care organization operating in Indiana. It contracts with the Indiana Family and Social Services Administration (FSSA) to provide health coverage to Medicaid-eligible residents, including children, adults, and dual-eligible beneficiaries. Drug benefits are governed by the Indiana Medicaid Preferred Drug List (PDL), which the state's Pharmacy and Therapeutics (P&T) Committee reviews quarterly.

The Role of the Preferred Drug List

Indiana Medicaid publishes a PDL that ranks medications by clinical and economic value. Drugs labeled "preferred" have no prior authorization requirement and carry the lowest cost-share for members. Drugs labeled "non-preferred" require prior authorization (PA) before the plan will pay. Apixaban (Eliquis) has historically appeared as a non-preferred brand-name drug on Indiana's PDL, meaning prescribers must document medical necessity before MDwise will approve a claim.

The Indiana FSSA updates its PDL regularly. Checking the current version at the Indiana Medicaid provider portal or calling MDwise member services at 1-800-356-1204 is the most reliable way to confirm current status for any given benefit year.

Why Formulary Placement Matters for Eliquis

Eliquis is a brand-name oral anticoagulant manufactured by Bristol-Myers Squibb and Pfizer. No FDA-approved generic apixaban existed for most Medicaid formularies until 2023, when the first generic versions entered the market following patent expiration. FDA generic drug approvals for apixaban list multiple authorized generics as of 2024, which may improve formulary access over time. Even with generics available, managed care plans often require a transition period before moving a drug to preferred status.

What Indications Does MDwise Typically Approve Eliquis For?

MDwise generally follows CMS and Indiana Medicaid guidance when evaluating prior authorization requests. Approved indications align with FDA-labeled uses for apixaban, which the FDA originally approved in 2012 for stroke and systemic embolism risk reduction in nonvalvular atrial fibrillation, and extended to DVT and PE treatment and prophylaxis in 2014. FDA prescribing information for apixaban outlines these indications.

Atrial Fibrillation

Nonvalvular atrial fibrillation (AFib) is the most common reason physicians prescribe Eliquis. The ARISTOTLE trial (N=18,201) demonstrated that apixaban reduced the rate of stroke or systemic embolism by 21% compared with warfarin (1.27% vs. 1.60% per year, P<0.001) and cut major bleeding by 31% (2.13% vs. 3.09% per year, P<0.001). ARISTOTLE was published in the New England Journal of Medicine in 2011. MDwise PA criteria for AFib typically require documentation of a CHA2DS2-VASc score of 2 or higher in men (1 or higher in women), consistent with American Heart Association guidelines.

DVT and Pulmonary Embolism

For acute DVT or PE treatment, apixaban is dosed at 10 mg twice daily for 7 days, then 5 mg twice daily. The AMPLIFY trial (N=5,395) showed apixaban was non-inferior to conventional enoxaparin-warfarin therapy for recurrent VTE (2.3% vs. 2.7%) and produced 69% less major bleeding (0.6% vs. 1.8%, P<0.001). AMPLIFY results are indexed on PubMed. MDwise may require documentation of the acute event, imaging confirmation, and a reason warfarin is unsuitable before approving apixaban for this indication.

Post-Surgical Prophylaxis

Apixaban carries FDA approval for DVT prophylaxis after hip or knee replacement surgery. The ADVANCE-3 trial (N=5,407) showed apixaban 2.5 mg twice daily reduced the composite of DVT, PE, and all-cause mortality by 64% compared with enoxaparin 40 mg daily after total hip replacement (1.4% vs. 3.9%, P<0.001). ADVANCE-3 is available on PubMed. Prior authorization for surgical prophylaxis typically requires the surgical date, procedure type, and expected duration of use.

How to Get Prior Authorization for Eliquis Through MDwise

Prior authorization is a formal request your prescriber submits to MDwise explaining why Eliquis is medically necessary for you specifically. The process has defined steps and timelines that federal Medicaid rules govern.

Step 1: Prescriber Submits the PA Request

Your physician, nurse practitioner, or PA submits a PA form to MDwise, either through the online provider portal or by fax. The form requires:

• Patient Medicaid ID and date of birth
• ICD-10 diagnosis code (e.g., I48.0 for paroxysmal AFib, I26.09 for acute PE without acute cor pulmonale)
• Requested drug, dose, and days' supply
• Clinical rationale explaining why a preferred anticoagulant is not appropriate
• Lab values if relevant (e.g., INR instability on warfarin, renal function)

Step 2: Step Therapy Documentation

MDwise often requires evidence that the patient has tried or has a contraindication to a preferred anticoagulant first. Warfarin remains the most commonly preferred option on Indiana Medicaid formularies because its cost is substantially lower. If a patient has documented labile INR values on warfarin (defined by some guidelines as time in therapeutic range below 65%), drug interactions, or a high fall risk increasing intracranial bleeding concern, those factors support moving directly to apixaban.

The American Heart Association/American College of Cardiology 2023 AFib guidelines state: "For patients with atrial fibrillation and CHA2DS2-VASc score of 2 or greater, oral anticoagulation is recommended, and NOACs are preferred over warfarin in patients who are eligible." The full 2023 ACC/AHA AFib guideline is available at the AHA journals site.

Step 3: MDwise Decision Timeline

Federal Medicaid rules require that standard PA decisions be issued within 3 business days. Urgent or expedited requests (when a delay could seriously jeopardize health) must be resolved within 24 hours. If MDwise denies the PA, the denial notice must include the specific clinical criteria not met and instructions for appealing.

Step 4: Appeal a Denial

If MDwise denies your PA request, you have the right to request an internal appeal within 30 days of the denial notice. If the internal appeal fails, you may request an external independent review or a Medicaid State Fair Hearing through the Indiana FSSA. Success rates on appeal improve when the prescriber submits additional peer-reviewed evidence, such as the ARISTOTLE or AMPLIFY trial data, alongside a clinical narrative.

Which Anticoagulants Are Preferred on MDwise and Indiana Medicaid?

Indiana Medicaid's PDL typically places warfarin at the lowest-cost preferred tier because it is a generic with decades of safety data. Among direct oral anticoagulants (DOACs), rivaroxaban (Xarelto) has at times appeared as a preferred DOAC on Indiana's PDL when the manufacturer negotiated a supplemental rebate with the state. Dabigatran (Pradaxa) and edoxaban (Savaysa) are also FDA-approved for AFib and VTE but tend to sit at non-preferred tiers as well.

Warfarin: Still Effective, Still Preferred by Payers

Warfarin reduces stroke risk in AFib by approximately 64% compared with placebo, based on a meta-analysis of six randomized trials (N=2,900) published in the Annals of Internal Medicine. That meta-analysis is indexed on PubMed. The main challenge is its narrow therapeutic index, the target INR range of 2.0 to 3.0 requires routine monitoring and is affected by diet, alcohol intake, and over 200 known drug interactions. The FDA warfarin prescribing information provides a full interaction table.

Rivaroxaban as a Potential Preferred DOAC Alternative

Rivaroxaban 20 mg once daily (with the evening meal) is FDA-approved for AFib stroke prevention. The ROCKET-AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for stroke prevention (1.7% vs. 2.2% per year, P<0.001 for non-inferiority) with similar major bleeding rates. ROCKET-AF is available in the New England Journal of Medicine. If rivaroxaban is preferred on the MDwise formulary at the time of prescribing, it may be worth a clinical conversation about whether it is an appropriate alternative for a given patient.

When Apixaban Is Clinically Superior

Apixaban has a distinct pharmacological profile: it is dosed twice daily, has the lowest renal clearance of the approved DOACs (27% renal excretion vs. 33% for rivaroxaban and 80% for dabigatran), and is the only DOAC with FDA approval for patients with end-stage renal disease on dialysis as of 2021. FDA label update for dialysis patients. For patients with advanced CKD (CrCl 15 to 29 mL/min) or on dialysis, apixaban may be the only guideline-supported DOAC option, which strengthens a PA request considerably.

The 2022 American College of Cardiology Expert Consensus Decision Pathway for anticoagulation in CKD states: "Apixaban is the preferred DOAC in patients with advanced CKD due to its limited renal clearance and emerging evidence base in dialysis patients." The ACC consensus document is hosted on the ACC/AHA journals.

Cost of Eliquis Without MDwise Coverage

If MDwise denies coverage or you are between enrollment periods, brand-name Eliquis without insurance averages $560, $620 for a 30-day supply of 5 mg twice-daily tablets at major retail pharmacies, based on GoodRx pricing data as of late 2024. Generic apixaban, where available, may cost $40, $80 per month depending on the pharmacy and dose. The Bristol-Myers Squibb/Pfizer Eliquis patient assistance program (Eliquis 360 Support) offers free medication to patients with income at or below 400% of the federal poverty level who do not have adequate insurance coverage.

Manufacturer Copay Cards

Bristol-Myers Squibb offers a copay assistance card that can reduce out-of-pocket cost to as low as $10 per month for commercially insured patients. This card is generally not usable in combination with Medicaid coverage, federal anti-kickback statute prohibitions apply, but can be relevant during a coverage gap or for patients transitioning between insurance types.

Pharmacy-Level Programs

Pharmacies such as Cost Plus Drugs (Mark Cuban Cost Plus Drug Company) list generic apixaban at substantially reduced prices. Checking FDA's list of approved apixaban generics and comparing at multiple pharmacies is worthwhile for any patient whose PA is denied pending appeal.

Clinical Considerations: Is Eliquis the Right Anticoagulant for Your Situation?

Insurance coverage aside, the choice of anticoagulant should be individualized. The following clinical factors commonly support selecting apixaban specifically over alternatives.

Renal Function

Apixaban requires dose reduction to 2.5 mg twice daily when two of three criteria are met: age 80 or older, weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. This "2-of-3" rule comes directly from the FDA prescribing label and the ARISTOTLE trial design. Dosing guidance is in the FDA label. Patients with advanced CKD who might otherwise need warfarin with its unpredictable INR behavior in renal disease are often the strongest candidates for apixaban PA approval.

Bleeding Risk

The HAS-BLED score quantifies bleeding risk in AFib patients on anticoagulation. A score of 3 or higher indicates high risk. In ARISTOTLE, apixaban produced fewer intracranial hemorrhages than warfarin (0.33% vs. 0.80% per year). Published in the New England Journal of Medicine. A patient with a prior intracranial bleed who nonetheless requires anticoagulation for high-stroke-risk AFib has a strong clinical argument for apixaban over warfarin.

Drug and Food Interactions

Warfarin interacts with vitamin K-rich foods, dozens of antibiotics, antifungals, and many cardiovascular drugs. Apixaban's interactions are narrower: strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole, ritonavir) require dose reduction or avoidance. The FDA interaction guidance is in the apixaban label. Patients on complex polypharmacy regimens sometimes tolerate apixaban more predictably than warfarin, a fact worth documenting in a PA request.

The HealthRX Anticoagulation Coverage Framework summarizes the key decision pathway: (1) confirm indication and CHA2DS2-VASc or VTE diagnosis; (2) assess renal function and select dose; (3) document warfarin candidacy and reasons for preference of apixaban; (4) submit PA with trial data; (5) if denied, appeal with renal or bleeding-risk data specific to the patient.

What MDwise Members Should Do Right Now

If you or your prescriber are waiting on an MDwise PA decision for Eliquis, three practical steps apply immediately.

First, ask your prescriber to document INR instability, renal function, or drug interactions in the PA narrative, not just the diagnosis code. PA reviewers are more likely to approve requests that address the specific clinical criteria in the denial checklist. Second, confirm whether generic apixaban is available at your pharmacy. As of 2024, the FDA has approved multiple generic apixaban products, and some Indiana pharmacies dispense them at significantly lower cost than brand Eliquis. FDA generic drug database lists current approvals. Third, if the PA is denied, submit the ARISTOTLE trial data, the 2023 ACC/AHA AFib guidelines, and any relevant ACC CKD consensus document as supporting literature in your appeal. Medicaid appeals that include guideline citations have a higher documented success rate than those that rely solely on the prescriber's clinical judgment alone.

The National Alliance of Mental Illness (NAMI) Indiana and the Indiana Legal Services Medicaid advocacy unit both offer free help navigating Medicaid coverage disputes for eligible members, a resource worth knowing for patients who cannot advocate on their own.